Saving changes...

Done

Error

Putting Emerging Lipids Data into Practice: New Treatments and Opportunities to Reduce Cardiovascular Risk

Putting Emerging Lipids Data into Practice: New Treatments and Opportunities to Reduce Cardiovascular Risk

Putting Emerging Lipids Data into Practice: New Treatments and Opportunities to Reduce Cardiovascular Risk

National Association for Continuing Education
National Association for Continuing Education
on behalf of National Association for Continuing Education

$20.00 $ 20.00 $ 20.00

$20.00 $ 20.00 $ 20.00

$ 20.00 $ 20.00 $ 20.00
$ 20.00 $ 20.00 $ 20.00
Normal Price: $20.00 $20.00

Review:

Launch date: 15 Feb 2018
Expiry Date: 14 Jan 2019

Last updated: 22 Aug 2018

Reference: 186998

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

Description

Welcome to the National Association for Continuing Education monograph from the NACE Clinical Updates for NPs and PAs 2017 conference.

Statins have been the mainstay of pharmacotherapy for dyslipidemia and reduction of
ardiovascular risk. The PCSK9 inhibitors are a new and exciting treatment option for hyperlipidemia that are changing the way those patients at the highest risk are being managed. Over the past several years, there have been several updates to ACC/AHA lipid treatment recommendations which leave many clinicians wondering what the best strategies are for their patients. This
educational program will discuss an approach to integrating new data into lipid management strategies for further improving cardiovascular outcomes in the highest risk patients.

Objectives

Objective 1: Review current recommendations for the use of non-statin therapies in the management of dyslipidemia.
After completing this program participants should be able to review current recommendations for the use of non-statin therapies in the management of dyslipidemia.
Objective 2: Explain the role of anti-PCSK9 monoclonal antibody therapy in
LDL-C reduction to achieve cardiovascular risk reduction.
After completing this program participants should be able to explain the role of anti-PCSK9 monoclonal antibody therapy in LDL-C reduction to achieve cardiovascular risk reduction.
Objective 3: Describe the findings from recent trials of dyslipidemia treatments on cardiovascular outcomes.
After completing this program participants should be able to describe the findings from recent trials of dyslipidemia treatments on cardiovascular outcomes.
Objective 4: Integrate new data into treatment strategies for further improving cardiovascular outcomes in the highest risk patients.
After completing this program participants should be able to integrate new data into treatment strategies for further improving cardiovascular outcomes in the highest risk patients.
National Association for Continuing Education

Author Information Play Video Bio

National Association for Continuing Education
on behalf of National Association for Continuing Education

The mission of the National Association for Continuing Education (NACE) is to offer continuing education opportunities to provide learners in the fields of medicine, behavioral health, education, and related disciplines, with the most up-to-date, science-based information that will enable them to increase their knowledge, competence, and professional performance to ultimately benefit their patients' health.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Continuing Medical Education (ACCME)
  • 1.00 Credits
  • American Association of Nurse Practitioners (AANP)
  • 1.00 Hours -
    Exam Pass Rate: 70

Faculty and Disclosures

Additional Contributors

Course Directors
Gregg Sherman, MD
Chief Medical Officer, NACE
Plantation, FL

Deborah Paschal, CRNP
Philadelphia, PA

Medical Writer
Josh Kilbridge
Kilbride Associates Healthcare Communications
San Francisco, CA

Course Reviewer
Robert L. Gillespie, MD, FACC, FASE, FASNC
Immediate Past Chairman of the Board
Association of Black Cardiologists
Director of Nuclear Imaging
Sharp Rees-Stealy Medical Group
San Diego, CA

Conflicts Declared

Conflicts of Interest declaration by Author:

Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosures are provided below.

Robert L. Gillespie, MD, FACC, FASE, FASNC, Course Reviewer, is a speaker for Astellas and Boston Scientific. He also serves as a consultant for Boston Scientific.

Gregg Sherman, MD, Co-Course Director, has no relationships to disclose.

Deborah Paschal, CRNP, Co-Course Director, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.

Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.

Cassandra A. McCullough, MBA, Activity Planning Committee, has no relationships to disclose.
Commercial Support
This activity is supported by educational funding provided by Amgen.

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error